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Abstract 19 
As microbial genomics makes increasingly important contributions to clinical and public health 20 
microbiology, the interpretation of whole genome sequence data by non-specialists becomes essential. 21 
In the absence of capsule-based vaccines, two protein-based vaccines have been used for the 22 
prevention of invasive serogroup B meningococcal disease (IMD), since their licensure in 2013/14. 23 
These vaccines have different components and different coverage of meningococcal variants. Hence, 24 
decisions regarding which vaccine to use in managing serogroup B IMD outbreaks require 25 
information about the index case isolate including: (i) the presence of particular vaccine antigen 26 
variants; (ii) the expression of vaccine antigens; and (iii) the likely susceptibility of its antigen 27 
variants to antibody-dependent bactericidal killing. To obtain this information requires a multitude of 28 
laboratory assays, impractical in real-time clinical settings, where the information is most urgently 29 
needed. To facilitate assessment for public health and clinical purposes, we synthesised genomic and 30 
experimental data from published sources to develop and implement the ‘Meningococcal Deduced 31 
Vaccine Antigen Reactivity’ (MenDeVAR) Index, which is publicly-available on PubMLST 32 
(https://pubmlst.org). Using whole genome sequences or individual gene sequences obtained from 33 
IMD isolates or clinical specimens, MenDeVAR provides rapid evidence-based information on the 34 
presence and possible immunological cross-reactivity of different meningococcal vaccine antigen 35 
variants. The MenDeVAR Index enables practitioners who are not genomics specialists to assess the 36 
likely reactivity of vaccines for individual cases, outbreak management, or the assessment of public 37 
health vaccine programmes. MenDeVAR has been developed in consultation with, but independently 38 
of, both vaccine manufacturers. 39 
Keywords: Meningococcal disease, Neisseria meningitidis, vaccines, Meningococcal Deduced 40 
Vaccine Antigen Reactivity (MenDeVAR), Meningococcal Antigen Typing System (MATS), 41 
Meningococcal Antigen Surface Expression (MEASURE) assay, serum bactericidal activity assay, 42 
outbreaks, whole genome sequencing, public health  43 
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Introduction 44 
Microbial whole genome sequencing (WGS) has advanced our understanding of microbial evolution, 45 
diversity, and pathogenicity. Since the first bacterial genome was sequenced in 1995, the technology 46 
has developed from dideoxynuclueotide terminator (Sanger) sequencing to multiplexed WGS 47 
platforms (1-3). Concomitantly, the cost of WGS has reduced substantially, increasing its availability 48 
and affordability worldwide; however, DNA sequencing itself is a first step, with multidisciplinary 49 
expertise required to exploit these complex large data sets to address particular questions and translate 50 
the results to public health action. Genomic technologies are increasingly incorporated into public 51 
health and clinical microbiology laboratories, where identifying and typing micro-organisms is critical 52 
to informing infectious disease management in individuals and populations. Extracting information 53 
from genomic data is important, but it is equally important to communicate these data promptly and 54 
effectively to relevant practitioners (4). Here we describe a generalizable framework for assimilating 55 
sequence data with phenotypic information, linking genotype to phenotype with the results presented 56 
as an easy to understand result for use by non-specialists.    57 
Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, is a serious infection with 58 
significant mortality and morbidity (5, 6). Diagnosis of IMD is either through bacterial culture and 59 
capsular group serotyping, or, in the absence of culture, by PCR testing, with additional 60 
discrimination provided by characterisation of capsule-encoding and protein antigen-encoding genes 61 
(7). IMD generally occurs sporadically but can occur in clusters and outbreaks, due to the 62 
transmission of hyperinvasive meningococcal variants generally or among individuals living in 63 
closed- or semi-closed communities such as schools, universities, military barracks, and extended 64 
households. Increasingly, real-time WGS of meningococcal isolates can direct public health 65 
investigations and interventions. 66 
Prevention of IMD is possible by immunisation, delivered either by routine programmes or in 67 
response to clusters or outbreaks. When they occur, such outbreaks are a public health priority, 68 
requiring the rapid identification of individuals at high risk from the meningococcal variant identified 69 
in the index case. Prophylactic antibiotics are provided to close contacts to prevent outbreak strain 70 
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transmission and vaccination offered where appropriate (8). While highly immunogenic conjugate 71 
protein-polysaccharide vaccines are available against invasive meningococci expressing capsular 72 
serogroups A, C, W, and Y (9), there are none against serogroup B meningococci, which are a major 73 
cause of IMD outbreaks and clusters in many countries. In 2013 and 2014, two protein-based 74 
meningococcal vaccines were licensed to assist in the prevention of serogroup B IMD. The particular 75 
protein antigens contained in the two vaccines, 4CMenB (Bexsero®) and rLP2086 (Trumenba®), were 76 
different and not specific to serogroup B meningococci.  These antigens also displayed 77 
immunologically significant protein sequence diversity (10, 11). Therefore, the two vaccines exhibit 78 
different degrees of possible protection against heterologous vaccine antigens and, consequently, there 79 
could be a need for frontline clinical and public health specialists to assess each vaccine rapidly in the 80 
context of a particular scenario, to inform decisions about vaccine implementation.  81 
Using WGS to provide clinically applicable information requires systematic and reproducible 82 
characterisation of genetic variation. Multilocus sequence typing (MLST), based on housekeeping 83 
genes, is the most widely-used approach to characterising bacterial variants, facilitating 84 
communication among laboratories internationally and the identification of hyperinvasive 85 
meningococci (12). Typing bacterial genetic diversity of medically important features, such as 86 
polysaccharide capsules (13, 14), antimicrobial resistance genes (15), and vaccine antigens (16) can 87 
be achieved through similar gene-by-gene approaches (17). For example, the Bexsero® Antigen 88 
Sequence Typing (BAST) scheme was established to characterise and describe vaccine antigen 89 
variants, using data derived through WGS or sequencing of individual genes (16).  90 
Both vaccines contain factor H binding protein (fHbp), one recombinant peptide variant in Bexsero® 91 
(peptide 1) and two native lipidated peptide variants in Trumenba® (peptides 45 and 55) (11). 92 
Bexsero® also contains the recombinant proteins, Neisserial heparin-binding antigen (NHBA, peptide 93 
2) and Neisseria adhesin A (NadA, peptide 8), combined with the PorA-containing (variable region 94 
(VR2), peptide 4) outer membrane vesicle from the MeNZB™ vaccine (10). The BAST scheme 95 
catalogues peptide presence/absence and variation, using deduced peptide sequences, but cannot infer 96 
protein expression or cross-reactivity. The Meningococcal Antigen Typing System (MATS) 97 
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laboratory assay was devised to estimate the proportion of diverse serogroup B disease strains 98 
prevented by Bexsero®, by assessing protein expression and cross-reactivity (18); however, MATS is 99 
not widely or immediately available in clinical settings and is time- and resource-intensive. Genetic 100 
MATS (gMATS) was developed to predict Bexsero® strain coverage using sequence and phenotypic 101 
MATS data.  At the time of writing, this algorithm was not available on an accessible, integrated 102 
platform for genome sequence data analysis, nor had it been updated to accommodate the description 103 
of additional variants (19). 104 
To perform genomic vaccine antigen analysis comprehensively requires an understanding of 105 
sequencing technology, genomic data quality control, and gene/peptide curation and analysis.  As of 106 
mid-2020, these skills were developing amongst healthcare scientists/clinicians, but were far from 107 
universal (4). Given the need to assess breadth of vaccine reactivity and to ensure genomic data are 108 
harnessed to maximise clinical and public health benefit, we developed the ‘Meningococcal Deduced 109 
Vaccine Antigen Reactivity’ (MenDeVAR) Index, publicly-accessible on PubMLST Neisseria 110 
website (20). By synthesising published, peer reviewed, experimental data with sequence data, the 111 
MenDeVAR Index provides a means for public health and clinical practitioners to extract easily 112 
understood, relevant information from genomic data in real-time.  113 
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Methods 114 
Vaccine antigen typing 115 
Allele-based typing schemes for each of the antigens included in Bexsero® and Trumenba® have been 116 
published. The BAST scheme was developed as a multi-locus, rapid, and scalable method to 117 
catalogue deduced peptide diversity of meningococcal vaccine antigens (16). The scheme includes 118 
five peptide components contained in the Bexsero® vaccine: fHbp; NHBA; NadA; and PorA VR1 and 119 
VR2. Typing of Trumenba® vaccine antigen fHbp was available with cross-referencing to the 120 
subfamily A and B nomenclature, on PubMLST Neisseria website (21, 22). Novel peptide variants are 121 
curated in real-time after submission to PubMLST, these curated databases form the basis of the 122 
MenDeVAR Index. 123 
Literature search 124 
Determining the extent to which either protein-based vaccine is protective against a given 125 
meningococcus requires an assessment for each vaccine component of the protein sequence variant 126 
present, its surface expression, its likely recognition by vaccine-induced antibodies, and finally the 127 
likelihood of bactericidal killing of the meningococcus in the presence of vaccinee serum. These 128 
factors were assessed using published experimental studies for each vaccine. For Bexsero®, the 129 
MATS assay was used, which was established to assess the breadth of vaccine coverage to diverse 130 
meningococcal strains (18, 23). MATS determines the antigenic variants of fHbp, NHBA, and NadA 131 
through sandwich ELISA, and their reactivity to pooled toddler serum (post-vaccination with three 132 
doses and booster), based on a collection of reference strains tested in serum bactericidal activity 133 
(SBA) assays. For Trumenba®, the Meningococcal Antigen Surface Expression (MEASURE) assay 134 
(24), a flow cytometric measurement of fHbp surface expression, was used. Additionally, SBA assays 135 
using serum from individuals immunised with Trumenba® (2 or 3 doses, varying dosing schedules) 136 
were included, as there was only one vaccine antigen. Only antigens tested in these assays were 137 
analysed as contributing to a cross-protective vaccine effect for the MenDeVAR Index (Figure 1).  138 
For Bexsero®, a literature search using the terms “Meningococcal Antigen Typing System” AND 139 
“Neisseria meningitidis” AND “vaccine” on 14th May 2020 yielded 44 studies published in English. 140 
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There were 13 studies eligible for assessment (Supplemental Table S1), pertaining to capsular group 141 
B IMD isolates (MATS is only validated for serogroup B), with data of sufficient detail to assess 142 
individual antigens and their predicted vaccine coverage. For Trumenba®, a literature search using the 143 
terms “meningococcal antigen surface expression (MEASURE) assay” AND “Neisseria meningitidis” 144 
AND “vaccine” on the 14th May 2020 yielded 12 studies published in English. One study contained 145 
MEASURE assay data for individual antigenic variants (Supplemental Table S2). Additionally, a 146 
literature search using the terms “serum bactericidal activity assay” AND “Neisseria meningitidis” 147 
AND “vaccine” AND “bivalent” on the 14th May 2020 yielded 28 studies published in English. 148 
Fifteen studies contained data to assess individual antigenic variants and their likelihood of providing 149 
protection using SBA assays (Supplemental Table S2). 150 
Criteria for defining cross-reactive antigens in the MenDeVAR Index  151 
To index the experimental data, thresholds were determined to define antigenic variants as either 152 
likely cross-reactive or not cross-reactive and the proportion of isolates with a given antigenic variant 153 
considered covered/protected through experimental assays was calculated. For each assay (MATS, 154 
MEASURE, and SBA), thresholds previously defined by the developers or the research community 155 
were employed. For the MATS assay, an antigenic variant was considered “covered” (i.e. would be 156 
susceptible to a vaccine-induced immune response) where the relative potency (RP) was greater than 157 
the positive bactericidal threshold (PBT) (18). For the MEASURE assay, an antigenic variant was 158 
considered “covered” if the mean fluorescent intensity (MFI) >1000 (24). For the SBA assay, 159 
antigenic variants were assessed through host immunogenicity, resulting in likely protection from 160 
infection. The accepted serological measure indicating likely protection by immunisation with 161 
meningococcal vaccines is either ≥4-fold rise in antibody titres between pre- and post-vaccination sera 162 
or a titre >1:4 (25, 26).  From the combined analysis of the experimental studies, if an antigenic 163 
variant had been tested in ≥5 isolates and ≥¾ of them were covered/protected, then the variant was 164 
considered cross-reactive (“amber”). If an antigenic variant had been tested in ≥5 isolates, and ≥¾ of 165 
them were not covered/protected, then the variant was considered not cross-reactive (“red”) (Figure 166 
1). 167 
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Development of data visualisation for the MenDeVAR Index 168 
For ease of data presentation, a red, amber, green ‘traffic light’ data interpretation was employed: 169 
“green” was assigned to meningococcal variants with ≥1 antigenic vaccine variant, based on exact 170 
peptide sequence match; “amber” was assigned to isolates with ≥1 antigenic variant demonstrated as 171 
cross-reactive in experimental studies; and, “red” was assigned to isolates where all antigenic variants 172 
were not exact matches and had been shown to not elicit cross-reactivity to vaccine variants. The 173 
designation “grey” was assigned to variants possessing antigenic variants untested in experimental 174 
assays at the time of writing or where such tests did not meet the threshold chosen to indicate cross-175 
reactivity. The MenDeVAR Index status of the variants, especially those designated as “grey”, will be 176 
updated in the light of the above criteria as further published information become available. 177 
The MenDeVAR Index was implemented on the PubMLST Neisseria website on the isolate record 178 
(Figure 2a). In addition, WGS data or individual gene sequences can be used to make a direct query 179 
on https://pubmlst.org/bigsdb?db=pubmlst_neisseria_mendevar, which outputs the MenDeVAR 180 
Index result, without the need to create isolate records or upload WGS data to the database (Figure 181 
2b). A written description is provided to aid those with colour vision deficits, where “green” means 182 
“exact”, “amber” means “cross-reactive”, “red” means “none”, and grey means “insufficient data”. 183 
Additional, supporting information is provided: (i) the antigenic determinant of the reactivity index; 184 
(ii) the assay used to determine cross-reactivity; (iii) specific references to studies including those 185 
antigens; and (iv) caveats to interpretation (Table 1). The MenDeVAR Index was also integrated with 186 
the BAST scheme (16), so the index appears as part of the BAST profile on the isolate record. Users 187 
can also perform a batch profile query selecting BAST scheme which outputs the MenDeVAR Index 188 
https://pubmlst.org/bigsdb?db=pubmlst_neisseria_seqdef&l=1&page=batchProfiles. 189 
 190 
Case studies 191 
To exemplify the application of the MenDeVAR Index, two published IMD outbreaks/clusters were 192 
analysed: a IMD outbreak amongst a semi-closed, Irish traveller community (2010-2013) (27); and a 193 
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university IMD outbreak in the USA (2016) (28). Both WGS data available through PubMLST and 194 
published antigenic variants determined through WGS were examined.  195 
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Results 196 
Cross-reactive vaccine antigens 197 
For Bexsero® vaccine, MATS studies (29-41) were identified through literature searches. With the 198 
exception of two studies (34, 40) that used PBT for fHbp of 0.012, all other antigen RP were assessed 199 
against the PBT of 0.021 for fHbp, 0.294 for NHBA, and 0.009 for NadA (18). For each antigenic 200 
variant of fHbp, NHBA, and NadA, the proportion of isolates with a RP>PBT was calculated. For 201 
fHbp, there were 139 peptides examined by MATS assay, 28 (20.1%) tested in ≥5 isolates. For 202 
NHBA there were 110 peptides, 30 (27.3%) tested in ≥5 isolates. For NadA, there were 22 peptides, 5 203 
(22.7%) tested in ≥5 isolates; peptide 8 is an exact sequence match but has been experimentally tested 204 
in only 3 isolates to date. For Trumenba® vaccine, each antigen tested by the MEASURE assay in one 205 
study (24) was evaluated. For fHbp, there were 9 peptides examined by MEASURE assay, 6 of which 206 
were tested in ≥5 isolates (Table 2). From SBA studies (42-56), there were 23 fHbp peptides 207 
examined by SBA assay, 23 (100.0%) tested in ≥5 isolates; peptide 55 is an exact sequence match but 208 
has not been experimentally tested to date. 209 
Antigenic variants that did not meet either cross-reactive or not cross-reactive threshold were 210 
designated as “grey”, indicating that insufficient data were available to make an assessment for this 211 
variant. This included variants: (i) tested in ≥5 isolates, with between ¼ and ¾ covered/protected 212 
(Table 2); (ii) tested in <5 isolates (for Bexsero® vaccine this was 111 fHbp peptides, 80 NHBA 213 
peptides, and 17 NadA peptides, and for Trumenba® vaccine 3 fHbp peptides tested by MEASURE 214 
assay); or (iii) not tested in experimental assays.  215 
Designation of isolates with the MenDeVAR Index 216 
A meningococcal variant was designated “green” if it contained at ≥1 exact sequence match to the 217 
vaccine antigenic variants. This was, for Bexsero®: fHbp peptide 1; NHBA peptide 2; NadA peptide 218 
8; and PorA VR2,4 (16, 57). Similarly, for Trumenba® this corresponded to fHbp peptides 45 or 55 219 
(11) (Table 2). The “amber” designation was a used if a meningococcus contained ≥1 antigenic 220 
variant deemed cross-reactive from experimental studies, from any of fHbp, NHBA or NadA (Table 221 
2). PorA peptides are not considered cross-reactive (58). Finally, the “red” designation was used for 222 
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meningococci where none of its antigens present were exact matches with the vaccine antigens and its 223 
antigen variants had been shown experimentally not to cross-react with antibodies elicited by the 224 
vaccine (Table 2). 225 
MenDeVAR Index: exemplar case studies  226 
Irish traveller community outbreak 227 
Retrospective analysis of a published IMD outbreak in the Republic of Ireland (2010-2013) (27), 228 
exemplified the potential use of the MenDeVAR Index in the context of a community outbreak, where 229 
a variety of clinical specimens were available. A total of eight cases were identified over 42-months 230 
(Table 3). The initial meningococcus, from Case A, was not cultured, but identification and typing 231 
data were acquired by PCR amplification and sequencing of MLST loci and fine-typing antigen-232 
encoding genes porA and fetA. PorA VR2 antigen 4 was present, an exact peptide sequence match to 233 
Bexsero®. There was insufficient data to inform the use of Trumenba®, which contains only fHbp 234 
proteins.  At the time of identification Case A was considered to be sporadic case and the appropriate 235 
public health action was antibiotic prophylaxis for close contacts. Using the MenDeVAR Index, the 236 
disease-associated meningococcus would have be designated “green” for Bexsero® and “grey” for 237 
Trumenba®. Of the seven cases subsequently linked to this case, only two were successfully cultured 238 
and WGS (Cases B and H), but five could have a MenDeVAR Index inferred from fine-typing antigen 239 
PorA, with respect to Bexsero® (Table 3).  Additional molecular fHbp typing of isolates would inform 240 
the use of Trumenba®, in a setting where the PorA is not variant 4. These data identified 75% (6/8) of 241 
isolates, two with WGS, with sufficient information to designate as MenDeVAR Index “green” for 242 
Bexsero® and two WGS isolates with “amber” for Trumenba® (Table 3).    243 
US university cluster 244 
A cluster of IMD occurring in the US (2016) (28) was examined to demonstrate the use the 245 
MenDeVAR Index in an institutional outbreak. In this cluster, two undergraduate students at a New 246 
Jersey university were diagnosed with serogroup B IMD, with meningococci isolated from the 247 
cerebrospinal fluid of both (28). These isolates were examined in real-time by WGS through the local 248 
public health department and were both sequence type 11 (clonal complex 11) and indistinguishable 249 
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(Table 3). Antigenic variant data provided in the publication was assessed, which provided data 250 
equivalent to that obtained by determining the antigenic variants through PCR and sequencing, if 251 
WGS had not been available. The meningococci causing the outbreak harboured fHbp variant 2 252 
peptide 19, an antigen which is cross-reactive with Trumenba® (“amber”) but not cross-reactive with 253 
Bexsero® (“red”). The outbreak strains also had: (i) no nadA gene present (“red”); (ii) PorA 10-1 254 
(“red”); and (iii) NHBA peptide 20, for which there is insufficient data to determine cross-reactivity 255 
with confidence (“grey”).  The MenDeVAR Index therefore designated these isolates “amber” for 256 
Trumenba® and “grey” for Bexsero®, the latter based solely on the NHBA variant present, with 257 
remaining antigens “red”. This information could have directed public health specialists to using 258 
Trumenba® early after IMD cluster definition was met, preventing delays in health protection 259 
interventions including mass vaccination campaigns, frequently required in university settings.  260 
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Discussion 261 
As bacterial genome sequencing has become increasingly accessible, the prospect of using genomic 262 
data for the benefit of public and individual health has become a reality. This opportunity is, however, 263 
fraught with challenges including: (i) the large and complex genomic datasets involved; (ii) the 264 
expertise required to understand the uses and limitations of WGS technologies; (iii) the increasing 265 
number and complexity of analysis tools; (iv) the requirement for skills with command-line interfaces; 266 
(v) insufficient bioinformatics or genomic epidemiology training amongst healthcare practitioners and 267 
scientists; and (vi) the diversity of the information sources that need to be integrated.  268 
Genome sequence data provide information on the presence or absence of genes associated with 269 
clinically relevant phenotypes e.g. antibiotic susceptibility, pathogenicity or vaccine antigens. The 270 
first step in exploiting this information is to extract relevant data for the identification of the genes and 271 
the protein variants they encode (typing). The second step is to index these types to the relevant 272 
phenotypic data. The third step is to present the result in an accessible format for non-genomics 273 
specialists to inform clinical decision-making. Here, we demonstrated the MenDeVAR Index, which 274 
combines these steps into a system for rapid, real-time assessment of protein-based meningococcal 275 
vaccine antigens, for public health and clinical microbiology application. 276 
The epidemiology of IMD varies geographically. Sporadic cases occur in countries where IMD is 277 
endemic, with clusters and outbreaks associated with high-density living conditions such as 278 
universities, military, or travelling communities (59). Endemic and hyper-endemic serogroup B IMD 279 
is problematic in many industrialised regions (60) and, in the absence of group B polysaccharide 280 
vaccines, protein-based vaccines (10, 11) have been developed. When IMD outbreaks emerge, it is 281 
essential to identify contacts and implement public health interventions rapidly. These include 282 
antibiotics and vaccinations, the latter, especially, requiring timely serogroup determination of the 283 
outbreak strain to ensure deployment of the appropriate vaccine (8). For serogroup B outbreaks, 284 
characterisation of peptide antigens is required to assess whether vaccination with Bexsero® and/or 285 
Trumenba® is likely to prevent disease (8). At the time of writing, this assessment was only possible 286 
using the laboratory assays established during the clinical development of these vaccines to assess 287 
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their breadth of antigenic coverage, namely the MATS, MEASURE, and SBA assays (18, 24, 26). 288 
These assays, however, required growth of the causative isolate, were confined to reference 289 
laboratories in a limited number of countries, and were time-consuming and expensive to perform (28, 290 
61). Consequently, they could not be relied upon to inform timely public health interventions. At the 291 
same time, WGS has become increasingly accessible to microbiology laboratories, often in real-time 292 
or near real-time. Further, where meningococcal cultures were not available, PCR of fine-typing and 293 
fHbp antigens provided information that complements the phenotypic data compiled within the 294 
MenDeVAR Index. Interpreted by local microbiologists and epidemiologists in the context of other 295 
pertinent information, the MenDeVAR Index offers a pragmatic assessment of likely susceptibility of 296 
outbreak strains to vaccine-induced immunity, based on published data.  297 
For the development of the MenDeVAR Index, robust, pragmatic criteria were used to assess the 298 
weight of evidence of potential antigenic cross-reactivity from four different sources. The SBA titre 299 
remained the accepted immune correlate of protection for assessing meningococcal vaccine efficacy; 300 
however, the SBA assay cannot be performed for routine IMD case isolates investigated as part of a 301 
public health response for many reasons including the availability of expertise, resources, time, 302 
human complement, and infant sera.  The use of MATS and MEASURE assays, as means of assessing 303 
the breadth of antigenic coverage, generated the best data available. Data from MEASURE assays, 304 
however, were limited at the time of assessment and the MATS assay was suggested to provide a 305 
conservative estimate compared to SBA titre (36, 38, 41). SBA data were not included for Bexsero®, 306 
which as a multi-component vaccine could induce multiple antibody responses. Although the gMATS 307 
assay also used genotypic predictors of MATS phenotype, and predicted cross-reactivity in agreement 308 
with the MenDeVAR Index using similar criteria (fHbp peptides: 1, 4, 10, 12, 14, 15, 37, 110, 144, 309 
215, 224, 232; NHBA peptides 1, 5, 10, 113, 243, 607) (19), the gMATs system was only applicable 310 
to one of the two available protein-based vaccines. Moreover, it excluded NadA antigens as 311 
predictors, included some unpublished data, and had not been updated. The MenDeVAR Index can 312 
assist public health and microbiology specialists by compiling and indexing the complex data 313 
available in the published evaluation of hundreds of meningococcal antigenic variants, a total of 29 314 
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studies at the time of writing.  The MenDeVAR Index is accessible through a user-friendly webpage 315 
(https://pubmlst.org/bigsdb?db=pubmlst_neisseria_mendevar) that facilitates the submission of WGS 316 
data as single or multiple contigs, or as part of an isolate record on PubMLST Neisseria website.   317 
The case studies explored here demonstrated how the MenDeVAR Index can be used as outbreaks 318 
developed, with the Irish outbreak showing how multiple types of information can be used effectively. 319 
Had the MenDeVAR Index been available at the time, it would have supported the use of the 320 
Bexsero® vaccine in this outbreak setting. The US university cluster demonstrated the difficulties 321 
faced by public health specialists in combining complex datasets from multiple sources in real-time to 322 
inform intervention strategies. This cluster was investigated by US Centers for Disease Control and 323 
the isolates were sent for laboratory testing at US universities, which is not a routine procedure. These 324 
analyses identified relatively low fHbp protein expression and low binding of NHBA peptide 2 325 
antisera to the outbreak strain, suggesting reduced likelihood of bactericidal killing (28). Based on 326 
these data along with additional information about persistence of antibody responses post-vaccination, 327 
immunisation of ~35,000 university students with Trumenba® was recommended. The public health 328 
team acknowledged that WGS data indicated the presence or absence of particular antigenic variants, 329 
which could be compared to the respective vaccine antigens. When variants were not exact sequence 330 
matches, however, there was no additional information available to indicate potential cross-protection 331 
offered by the vaccine. In the case of this outbreak, the MenDeVAR Index would have supported the 332 
use of Trumenba®, solely on the basis of WGS data.  333 
There are limitations to using the MenDeVAR Index, as it is based on WGS data linked to 334 
information from published in vitro MATS, MEASURE, and SBA serological studies, (Table 1). 335 
These assays are not perfect surrogates of protection for a variety of reasons including the age groups 336 
used to establish the assays and the provenance of the isolates used in their development. Further, at 337 
the time of writing, the expression of the antigens could not be reliably inferred or predicted from 338 
WGS data, although some fHbp promoter and intergenic regions had been correlated with protein 339 
expression (62, 63). Finally, the MenDeVAR Index applies to only to possible direct protection 340 
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against IMD, with no information available about possible herd immunity due to the lack of evidence 341 
to suggest either vaccine impacted oropharyngeal carriage of serogroup B meningococci (64-66).  342 
In conclusion, we present a generalisable multi-locus gene-by-gene framework for interpreting 343 
complex genomic datasets that can be used by practitioners to address clinical questions in a timely 344 
manner. Specifically, the MenDeVAR Index combines genomic and experimental data to provide a 345 
rational, evidence-based, estimate of the likelihood that either of the meningococcal protein-based 346 
vaccines offers protection against a given meningococcus. To ensure broad accessibility, the 347 
MenDeVAR Index is implemented with a ‘red’, ‘amber’, and ‘green’ interpretive interface that is easy 348 
to use and informative for practitioners without expertise in genomic analysis.  In the light of new 349 
published evidence, the MenDeVAR Index can be regularly re-evaluated using the criteria described 350 
here, adjusting antigenic variant designations accordingly, to ensure that public health and clinical 351 
microbiologists globally benefit from the latest research findings. 352 
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Figure legends 617 
Figure 1: The Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index algorithm 618 
used to identify which antigens are included as cross-reactive in the combined analysis of published 619 
experimental data from: Meningococcal Antigen Typing System (MATS) (18); Meningococcal 620 
Antigen Surface Expression (MEASURE) assay (24); and serum bactericidal activity (SBA) assay 621 
(27). RP (relative potency), PBT (Positive bactericidal threshold), MFI (mean fluorescence intensity). 622 
 623 
Figure 2: (a) The Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index as it 624 
appears on the isolate record page of the https://PubMLST/org/neisseria website. The provenance data 625 
shows the PubMLST id is 19992, states this is a serogroup B meningococcal isolate from the Eastern 626 
region of the UK, collected from invasive disease in 2010. The MenDeVAR Index is shown under the 627 
secondary metadata heading, and shows this isolate contains cross-reactive antigens for both vaccines, 628 
with fHbp peptide 15 the antigen used to determine this through the MATS assay for Bexsero® and 629 
the MEASURE and SBA assays for Trumenba®, reference shown with PubMed ID (PMID).  (b) The 630 
web interface to search using genome sequence, individual genes or whole genome data to output the 631 
MenDeVAR Index. 632 
Table 1: The caveats that are listed on the PubMLST Neisseria website when interpreting the 633 
Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index. 634 
Table 2: Vaccine antigen variants for the protein-based meningococcal vaccines Bexsero® (4CMenB) 635 
and Trumenba® (rLP2086) and their designation by Meningococcal Deduced Vaccine Antigen 636 
Reactivity (MenDeVAR) Index as: “green”, exact matches to the sequence variants; “amber”, cross-637 
reactive in experimental studies; “red”, not cross-reactive in experimental studies; “grey”, insufficient 638 
data”. fHbp, factor H binding protein; NHBA, Neisserial heparin-binding antigen; NadA, Neisseria 639 
adhesin A; PorA VR2, Porin A variable region. 640 
 641 
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24 
 
Table 3: Two examples of outbreak/clusters from published literature, showing the molecular typing 632 
data used to determine the MenDeVAR (Meningococcal Deduced Vaccine Antigen Reactivity) Index. 633 
ST, sequence type; cc, clonal complex; PorA VR, Porin A variable region; FetA, enterobactin receptor 634 
FetA; fHbp, factor H binding protein; NHBA, Neisserial heparin-binding antigen; NadA, Neisseria 635 
adhesin A; BAST, Bexsero® Antigen Sequence Type; —, no data. 636 
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Combined analysis of: 
Bexsero® (4CMenB): all published MATS assay data 
Trumenba®  (rLP2086): all published MEASURE and SBA assay data  
Identify antigenic variants that have been tested in ≥5 isolates 
MATS  
assay 
Not reactive 
≤¼ of these have RP 
> PBT 
Insufficient data 
¼ to ¾ of these have 
RP > PBT 
Cross-reactive 
≥ ¾ of these have RP 
> PBT 
≤¼ of these have  
MFI > 1000 
¼ to ¾ of these 
have MFI > 1000 
≥ ¾ of these have 
MFI > 1000 
≤¼ of vaccinees have 
≥4-fold response to 
vaccination or SBA 
titres >1:4 
¼ to ¾ of vaccinees 
have ≥4-fold response 
to vaccination or SBA 
titres >1:4 
≥¾ of vaccinees 
have ≥4-fold response 
to vaccination or SBA 
titres >1:4 
SBA  
assay 
MEASURE 
assay 
Trumenba®  (rLP2086) vaccine Bexsero®  (4CMenB) vaccine 
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 Bexsero
®
 vaccine Trumenba
®
 vaccine 
Source of data 
These data combine multiple sources of information including: peptide sequence identity through whole genome 
sequencing; experimental assays developed as indirect measures of the breadth of vaccine protection against diverse 
meningococci; and assays developed to assess immunogenicity.  
Protein expression 
We have not inferred protein expression from genomic data, therefore there may be isolates that possess genes but do no 
express the protein in vivo. 
Cross-reactivity definition  
An antigenic variant was considered cross-reactive if it had been tested in ≥5 isolates/subjects and was above the accepted 
threshold in ≥3/4 of those isolates. This was established through combined analysis of published experimental studies 
(PMID provided for each variant), not from genomic data. 
Meningococcal isolate 
source 
These assays were based on serogroup B disease isolates for both vaccines. 
Experimental assays 
 Meningococcal Antigen Typing System 
(MATS) assay. 
 Meningococcal antigen surface expression (MEASURE) 
assay. 
 Serum bactericidal activity (SBA) assay. 
Age of vaccinees  
 For MATS assay development, Bexsero
®
 vaccine 
recipients were infants who had received 3 doses of 
vaccine and then a booster at 12 months.  
 The pooled sera used for the MATS assay were taken 
from the toddlers at 13 months of age. 
 The age of vaccine recipients in the experimental studies 
varies widely, ranging from toddlers to adults, and needs 
to be taken into consideration when interpreting results.  
 Vaccine studies used different schedules and doses of 
vaccines. 
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MenDeVAR Index Antigen requirement (of 
fHbp, NHBA, NadA, 
and/or PorA VR2) 
fHbp peptide(s) NHBA peptide(s) NadA peptide(s) PorA VR2 
peptide 
Bexsero vaccine         
Green 
(exact) 
≥1 1 2 8 4 
Amber 
(cross-reactive) 
≥1 4, 10, 12, 14, 15, 37, 110, 
144, 215, 232  
1, 5, 10, 113, 243, 607 3, 6  None 
Red 
(none) 
All 4 16, 19, 21, 22, 24, 25, 29, 30, 
31, 45, 47, 59, 76, 109, 119  
6, 9, 17, 18, 25, 30, 31, 43,47, 63, 
112, 120, 160, 187, 197 
1, 21, 100 ≠4 
Grey 
(insufficient data) 
None of the above 13, 321, and other antigens 
that have not been 
experimentally tested 
3, 20, 21, 24, 29, 115, 118, 130, and 
other antigens that have not been 
experimentally tested 
Any antigens that have not 
been experimentally tested 
None 
Trumenba vaccine         
Green 
(exact) 
fHbp 45, 55       
Amber 
(cross-reactive) 
fHbp 1, 4, 13, 14, 15, 16, 19, 21, 
23, 25, 30, 47, 49, 76, 87, 
180, 187, 252, 276, 510 
      
Red 
(none) 
fHbp None       
Grey 
(insufficient data) 
None of the above 13, 24, or other antigens that 
have not been 
experimentally tested 
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Case Year Capsular group ST cc 
PorA 
typing 
FetA 
typing 
fHbp 
peptide 
NHBA 
peptide 
NadA 
peptide 
PorA 
VR1 
PorA 
VR2 BAST 
Bexsero 
MenDeVAR 
Index 
Trumenba  
MenDeVAR 
Index 
PubMLST 
id 
Irish traveller community outbreak             
Case A 2010 B 
Incomplete 
MLST 
profile 
ST-
41/44 
complex 
7-2, 4 F1-21 — — — 7-2 4 Unable to assign Green Grey 
 
Case B 2010 B 6697 
ST-
41/44 
complex 
7-2, 4 F1-21 4 607 0 7-2 4 381 Green Amber 26834 
Case C 2011 B 6697 
ST-
41/44 
complex 
7-2, 4 F5-12 — — — 7-2 4 Unable to assign   Green Grey 
 
Case D 2012 B 
Incomplete 
MLST 
profile 
Unable 
to assign   — — — — — — — 
Unable to 
assign   
   
Case E 2013 B 6697 
ST-
41/44 
complex 
7-2, 4 F5-12 — — — 7-2 4 Unable to assign   Green Grey 
 
Case F 2013 B 
Incomplete 
MLST 
profile 
ST-
41/44 
complex 
7-2, 4 — — — — 7-2 4 Unable to assign   Green Grey 
 
Case G 2013 B No data Unable to assign   — — — — — — — 
Unable to 
assign   
   
Case H 2013 B 6697 
ST-
41/44 
complex 
7-2, 4 F5-12 4 truncated 0 7-2 4 
Incomple
te BAST 
profile 
Green Amber 30743 
U.S. university cluster              
Case 1 2016 B 11 11 5-1, 10-1 — 19 20 0 5-1 10-1 3545 Grey Amber 
 
Case 2 2016 B 11 11 5-1, 10-1 — 19 20 0 5-1  10-1 3545 Grey Amber 
 
 
 on N
ovem
ber 20, 2020 by guest
http://jcm
.asm
.org/
D
ow
nloaded from
 
